In the News: Tasigna® Approved for Chronic Myeloid Leukemia (CML)
The United States Food and Drug Administration (FDA) has approved Tasigna® (nilotinib) for the treatment of chronic and accelerated-phase chronic myeloid leukemia (CML) for patients who are not able to tolerate or who have stopped responding to Gleevec® (imatinib). Tasigna® is an agent that also targets the same protein as Gleevec but through a different [...]